A Phase 2 interventional study of Tirzepatide and Placebo in Overweight, Obesity and Chronic Kidney Disease, sponsored by Eli Lilly and Company. Completed at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D).
The study will last about 56 weeks and include up to 12 visits.
3,670 studies on the registry are indexed under Overweight; 850 are open to participants now.
This study's enrollment of 134 is above the median of 73 across 3,175 interventional studies indexed under Overweight.
Browse Overweight studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
All participants with or without diabetes:
Participants without diabetes:
Participants with Type 2 diabetes:
Exclusion Criteria:
All participants:
Participants with T2D:
Tirzepatide administered subcutaneously (SC)
Drug: Tirzepatide
Placebo administered SC
Drug: Placebo
Administered SC
Administered SC
Percent Change from Baseline in Renal Sinus Fat Content (MRI)
Time frame: Baseline, Week 52
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 52
Percent Change from Baseline in Renal Fat Content (MRI Proton Density Fat Fraction)
Time frame: Baseline, Week 52
Percent Change from Baseline in Renal Blood Flow (Phase-Contrast MRI)
Time frame: Baseline, Week 52
Change from Baseline in Apparent Diffusion Coefficient (ADC) MRI
Time frame: Baseline, Week 52
Change from Baseline in Glomerular Filtration Rate (GFR) Iohexol Clearance in Milliliter/Minute/Square Meter (ml/min/m²)
Time frame: Baseline, Week 52
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, Week 52
Change from Baseline in 24-hour Urinary Albumin Excretion (UAE) in Milligram/24 Hours (mg/24h)
Time frame: Baseline, Week 52
Percent Change from Baseline in Urine Albumin-to-Creatine Ratio (UACR) in Participants With Baseline ≥30 mg/g
Time frame: Baseline, Week 52
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company